Symbols

CADL

Candel Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

Significant Net Income Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CADL

Candel Therapeutics, Inc.

A late clinical stage biopharmaceutical company that develops novel oncolytic viral immunotherapies

Industry

Biological Technology

Established Date

Listing Date

07/27/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.candeltx.com

Security Type

Common stock

Office address

117 Kendrick St, Suite 450, Needham, MA 02494

Business

Introduction

Candel Therapeutics, Inc., was incorporated in Delaware in June 2003. The company is a clinical-stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies designed to induce a systemic anti-tumor immune response. Its lead drug candidate, aglatimagene besadenovec, is an adenovirus-based therapy that is being studied in a variety of solid tumor indications.

Company Financials

EPS

CADL has released its 2025 Q4 earnings. EPS was reported at -0.54, versus the expected -0.25, missing expectations. The chart below visualizes how CADL has performed over recent quarters, highlighting trends in earnings surprises.